{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06508463",
            "orgStudyIdInfo": {
                "id": "MC1684 Arm E"
            },
            "secondaryIdInfos": [
                {
                    "id": "NCI-2017-00049",
                    "type": "REGISTRY",
                    "domain": "CTRP (Clinical Trial Reporting Program)"
                },
                {
                    "id": "MC1684",
                    "type": "OTHER",
                    "domain": "Mayo Clinic"
                },
                {
                    "id": "P30CA015083",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/P30CA015083"
                },
                {
                    "id": "16-005474",
                    "type": "OTHER",
                    "domain": "Mayo Clinic Institutional Review Board"
                },
                {
                    "id": "R01CA262613",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/R01CA262613"
                }
            ],
            "organization": {
                "fullName": "Mayo Clinic",
                "class": "OTHER"
            },
            "briefTitle": "Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma",
            "officialTitle": "Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "intravenous-vesicular-stomatitis-virus-in-patients-with-peripheral-t-cell-lymphoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2024-01-05",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2032-04-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-07-12",
            "studyFirstSubmitQcDate": "2024-07-12",
            "studyFirstPostDateStruct": {
                "date": "2024-07-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-17",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-19",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Mayo Clinic",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Cancer Institute (NCI)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus (VSV) carrying the human (h) sodium iodide symporter (NIS) and Interferon (IFN) beta (\u03b2) genes (VSV-hIFN\u03b2-NIS) in combination with ipilimumab and cemiplimab in patients with T-cell lymphoma. A virus, called VSV-hIFN\u03b2-NIS, which has been changed in a certain way, may be able to kill cancer cells without damaging normal cells. Immunotherapy with ipilmumab and cemiplimab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.",
            "detailedDescription": "PRIMARY OBJECTIVE: To determine the maximum tolerated dose (MTD) of VSV-hIFN\u03b2-NIS in combination with ipilimumab and cemiplimab in patients with T-cell lymphoma \\[Group E\\].\n\nPatients undergo computed tomography (CT) scan, position emission tomography (PET) scan throughout the study. Patients may undergo tumor biopsy, bone marrow biopsy and blood sample collection throughout the study.\n\nAfter completion of study treatment, patients are followed up for 28 days, and then every 3 months for up to 1 year or until progressive disease, then every 6 months for 1 year."
        },
        "conditionsModule": {
            "conditions": [
                "Peripheral T Cell Lymphoma",
                "Relapsed Peripheral T-Cell Lymphoma",
                "Peripheral T-Cell Lymphoma, Not Otherwise Specified",
                "Anaplastic Large Cell Lymphoma",
                "Mycosis Fungoides",
                "Relapsed Anaplastic Large Cell Lymphoma",
                "Relapsed Mycosis Fungoides"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Group E (VSV-IFN\u03b2-NIS, ipilimumab, cemiplimab) - Peripheral T-cell lymphoma (PTCL) only",
                    "type": "EXPERIMENTAL",
                    "description": "PTCL patients receive VSV-IFN\u03b2-NIS IV over 30 minutes on day 1, ipilimumab IV over 30 minutes on day -3 and cemiplimab IV over 30 minutes on day -3 in the absence of disease progression or unacceptable toxicity. Patients undergo SPECT, CT scan, PET scan throughout the study. Patients may undergo tumor biopsy, bone marrow biopsy and blood sample collection throughout the study.",
                    "interventionNames": [
                        "Procedure: Biopsy",
                        "Procedure: Biospecimen Collection",
                        "Procedure: Bone Marrow Biopsy",
                        "Procedure: Computed Tomography",
                        "Procedure: Positron Emission Tomography",
                        "Biological: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter",
                        "Procedure: Single Photon Emission Computed Tomography",
                        "Biological: Cemiplimab",
                        "Biological: Ipilimumab"
                    ]
                },
                {
                    "label": "Group E (VSV-IFN\u03b2-NIS, ipilimumab, cemiplimab) - PTCL Expansion Cohort",
                    "type": "EXPERIMENTAL",
                    "description": "PTCL patients receive VSV-IFN\u03b2-NIS IV over 30 minutes on day 1, ipilimumab IV over 30 minutes on day -3 and cemiplimab IV over 30 minutes on day -3 in the absence of disease progression or unacceptable toxicity. Patients undergo SPECT, CT scan, PET scan throughout the study. Patients may undergo tumor biopsy, bone marrow biopsy and blood sample collection throughout the study.",
                    "interventionNames": [
                        "Procedure: Biopsy",
                        "Procedure: Biospecimen Collection",
                        "Procedure: Bone Marrow Biopsy",
                        "Procedure: Computed Tomography",
                        "Procedure: Positron Emission Tomography",
                        "Biological: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter",
                        "Procedure: Single Photon Emission Computed Tomography",
                        "Biological: Cemiplimab",
                        "Biological: Ipilimumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "PROCEDURE",
                    "name": "Biopsy",
                    "description": "Undergo tumor biopsy",
                    "armGroupLabels": [
                        "Group E (VSV-IFN\u03b2-NIS, ipilimumab, cemiplimab) - PTCL Expansion Cohort",
                        "Group E (VSV-IFN\u03b2-NIS, ipilimumab, cemiplimab) - Peripheral T-cell lymphoma (PTCL) only"
                    ],
                    "otherNames": [
                        "BIOPSY_TYPE",
                        "Bx"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Biospecimen Collection",
                    "description": "Undergo blood sample collection",
                    "armGroupLabels": [
                        "Group E (VSV-IFN\u03b2-NIS, ipilimumab, cemiplimab) - PTCL Expansion Cohort",
                        "Group E (VSV-IFN\u03b2-NIS, ipilimumab, cemiplimab) - Peripheral T-cell lymphoma (PTCL) only"
                    ],
                    "otherNames": [
                        "Biological Sample Collection",
                        "Biospecimen Collected",
                        "Specimen Collection"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Bone Marrow Biopsy",
                    "description": "Undergo bone marrow biopsy",
                    "armGroupLabels": [
                        "Group E (VSV-IFN\u03b2-NIS, ipilimumab, cemiplimab) - PTCL Expansion Cohort",
                        "Group E (VSV-IFN\u03b2-NIS, ipilimumab, cemiplimab) - Peripheral T-cell lymphoma (PTCL) only"
                    ],
                    "otherNames": [
                        "Biopsy of Bone Marrow",
                        "Biopsy, Bone Marrow"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Computed Tomography",
                    "description": "Undergo SPECT/CT",
                    "armGroupLabels": [
                        "Group E (VSV-IFN\u03b2-NIS, ipilimumab, cemiplimab) - PTCL Expansion Cohort",
                        "Group E (VSV-IFN\u03b2-NIS, ipilimumab, cemiplimab) - Peripheral T-cell lymphoma (PTCL) only"
                    ],
                    "otherNames": [
                        "CAT",
                        "CAT Scan",
                        "Computed Axial Tomography",
                        "Computerized Axial Tomography",
                        "Computerized axial tomography (procedure)",
                        "Computerized Tomography",
                        "CT",
                        "CT Scan",
                        "tomography"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Positron Emission Tomography",
                    "description": "Undergo PET scan",
                    "armGroupLabels": [
                        "Group E (VSV-IFN\u03b2-NIS, ipilimumab, cemiplimab) - PTCL Expansion Cohort",
                        "Group E (VSV-IFN\u03b2-NIS, ipilimumab, cemiplimab) - Peripheral T-cell lymphoma (PTCL) only"
                    ],
                    "otherNames": [
                        "Medical Imaging, Positron Emission Tomography",
                        "PET",
                        "PET Scan",
                        "Positron emission tomography (procedure)",
                        "Positron Emission Tomography Scan",
                        "Positron-Emission Tomography",
                        "proton magnetic resonance spectroscopic imaging",
                        "PT"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter",
                    "description": "Given IV",
                    "armGroupLabels": [
                        "Group E (VSV-IFN\u03b2-NIS, ipilimumab, cemiplimab) - PTCL Expansion Cohort",
                        "Group E (VSV-IFN\u03b2-NIS, ipilimumab, cemiplimab) - Peripheral T-cell lymphoma (PTCL) only"
                    ],
                    "otherNames": [
                        "Oncolytic VSV-hIFNbeta-NIS",
                        "Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter",
                        "Voyager-V1",
                        "VSV-expressing hIFNb and NIS",
                        "VSV-hIFNb-NIS",
                        "VSV-hIFNbeta-NIS",
                        "VV1",
                        "VSV-hIFN\u03b2-NIS"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Single Photon Emission Computed Tomography",
                    "description": "Undergo SPECT/CT",
                    "armGroupLabels": [
                        "Group E (VSV-IFN\u03b2-NIS, ipilimumab, cemiplimab) - PTCL Expansion Cohort",
                        "Group E (VSV-IFN\u03b2-NIS, ipilimumab, cemiplimab) - Peripheral T-cell lymphoma (PTCL) only"
                    ],
                    "otherNames": [
                        "Medical Imaging, Single Photon Emission Computed Tomography",
                        "Single Photon Emission Tomography",
                        "Single-Photon Emission Computed",
                        "single-photon emission computed tomography",
                        "SPECT",
                        "SPECT imaging",
                        "SPECT SCAN",
                        "SPET",
                        "ST",
                        "tomography, emission computed, single photon",
                        "Tomography, Emission-Computed, Single-Photon"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Cemiplimab",
                    "description": "Given IV",
                    "armGroupLabels": [
                        "Group E (VSV-IFN\u03b2-NIS, ipilimumab, cemiplimab) - PTCL Expansion Cohort",
                        "Group E (VSV-IFN\u03b2-NIS, ipilimumab, cemiplimab) - Peripheral T-cell lymphoma (PTCL) only"
                    ],
                    "otherNames": [
                        "1801342-60-8",
                        "Cemiplimab RWLC",
                        "Cemiplimab-rwlc",
                        "Immunoglobulin G4",
                        "Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal REGN2810 Heavy Chain)",
                        "Disulfide with Human Monoclonal REGN2810 kappa-chain",
                        "Libtayo",
                        "REGN2810"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Ipilimumab",
                    "description": "Given IV",
                    "armGroupLabels": [
                        "Group E (VSV-IFN\u03b2-NIS, ipilimumab, cemiplimab) - PTCL Expansion Cohort",
                        "Group E (VSV-IFN\u03b2-NIS, ipilimumab, cemiplimab) - Peripheral T-cell lymphoma (PTCL) only"
                    ],
                    "otherNames": [
                        "Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody",
                        "BMS-734016",
                        "Ipilimumab Biosimilar CS1002",
                        "MDX-010",
                        "MDX-CTLA4",
                        "Yervoy"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of adverse events of grade 3 or higher",
                    "description": "Assessed by the Common Terminology Criteria for Adverse Events version 4.0. The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns (by cohort and overall). Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration. The rate of grade 3 or higher non-hematologic adverse events, and the rate of grade 4 or higher adverse event (hematologic and non-hematologic) will be computed each with a 95% exact binomial confidence.",
                    "timeFrame": "Up to 2 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Clinical response",
                    "description": "The number of responses \\[complete response (CR) or partial response (PR)\\] will be summarized by simple descriptive summary statistics.",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Progression-free survival",
                    "description": "The distribution of survival time will be estimated using the method of Kaplan-Meier (overall, by dose level, and by disease type).",
                    "timeFrame": "From registration to disease progression or death due to any cause, assessed up to 2 years"
                },
                {
                    "measure": "Overall survival",
                    "description": "The distribution of survival time will be estimated using the method of Kaplan-Meier (overall, by dose level, and by disease type).",
                    "timeFrame": "From registration to death due to any cause, assessed up to 2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \\>= 18 years\n* Relapsed or refractory:\n\n  * Group E only: Relapsed peripheral T-cell lymphoma (PTCL) of the following histologies: peripheral T-cell lymphoma-NOS (PTCL-NOS); anaplastic large cell (ALCL), and mycosis fungoides (MF)\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\\< 2 times upper limit of normal (ULN) (obtained =\\< 15 days prior to registration)\n* Creatinine =\\< 2.0 mg/dL (obtained =\\< 15 days prior to registration)\n* Direct bilirubin =\\< 1.5 x ULN (obtained =\\< 15 days prior to registration)\n* International normalized ratio (INR)/prothrombin time (PT) and activated partial thromboplastin time (aPTT) =\\< 1.5 x ULN (obtained =\\< 15 days prior to registration)\n* If baseline liver disease, Child Pugh score not exceeding class A (obtained =\\< 15 days prior to registration)\n* Negative pregnancy test for persons of child-bearing potential (obtained =\\< 15 days prior to registration)\n* FOR T-Cell Lymphoma (TCL)/B-Cell Lymphoma (BCL) ONLY: Absolute Neutrophil Count (ANC) \\>= 1,000/microliter (\u03bcL) (obtained =\\< 14 days prior to registration)\n* FOR TCL/BCL ONLY: Platelets \\>= 100,000/\u03bcL (obtained =\\< 14 days prior to registration)\n* FOR TCL/BCL ONLY: Hemoglobin \\>= 8.5 g/dl (obtained =\\< 14 days prior to registration)\n* FOR TCL/BCL ONLY: Measurable disease by CT or magnetic resonance imaging (MRI): must have at least one lesion that has a single diameter of \\> 2 cm or tumor cells in the blood \\> 5 x 10\\^9/L; NOTE: skin lesions can be used if the area is \\> 2 cm in at least one diameter and photographed with a ruler and the images are available in the medical record\n* Absence of active central nervous system (CNS) involvement; NOTE: pre-enrollment lumbar puncture not mandatory\n* Ability to provide written informed consent\n* Willingness to return to Mayo Clinic for follow-up\n* Life expectancy \\>= 12 weeks\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2\n* Willing to provide mandatory biological specimens for research purposes\n\nExclusion Criteria:\n\n* Availability of and patient acceptance of curative therapy\n* Uncontrolled infection\n* Active tuberculosis or hepatitis, or chronic hepatitis\n* Any of the following prior therapies:\n\n  * Chemotherapy (IMIDs, alkylating agents, proteosome inhibitors) =\\< 2 weeks prior to registration\n  * Immunotherapy (monoclonal antibodies) =\\< 4 weeks prior to registration\n  * Experimental agent in case of Acute Myeloid Leukemia (AML) or TCL within 4 half-lives of the last dose of the agent\n* New York Heart Association classification III or IV, known symptomatic coronary artery disease, or symptoms of coronary artery disease on systems review, or known cardiac arrhythmias \\[atrial fibrillation or supraventricular tachycardia (SVT)\\]\n* Active CNS disorder or seizure disorder or known CNS disease or neurologic symptomatology; in case of AML active CNS involvement as detected by lumbar puncture or neuro-imaging (only to be done if clinically indicated)\n* Human immunodeficiency virus (HIV) positive test result or other immunodeficiency or immunosuppression\n* Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (used for a non-Food and Drug Administration \\[FDA\\] approved indication and in the context of a research investigation);\n\n  * NOTE: in TCL, patients may use topical emollients or corticosteroids, acetic acid soaks, etc. to control pruritis and prevent infection; no topical chemotherapy is allowed (no topical nitrogen mustard)\n* Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:\n\n  * Pregnant women or women of reproductive ability who are unwilling to use effective contraception\n  * Nursing women\n  * Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 4 weeks after stopping treatment\n* ADDITIONAL EXCLUSION CRITERIA FOR GROUP E (COMBINATION WITH IPILIMUMAB AND CEMIPLIMAB) ONLY:\n\n  * Diagnosis of AML\n  * Diagnosis of Angioimmunoblastic T-cell Lymphoma (AITL)\n  * Hypersensitivity to ipilimumab or its excipients",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "overallOfficials": [
                {
                    "name": "Kah Whye Peng, Ph.D.",
                    "affiliation": "Mayo Clinic in Rochester",
                    "role": "PRINCIPAL_INVESTIGATOR"
                },
                {
                    "name": "Nora Bennani, M.D.",
                    "affiliation": "Mayo Clinic in Rochester",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Mayo Clinic in Arizona",
                    "status": "RECRUITING",
                    "city": "Scottsdale",
                    "state": "Arizona",
                    "zip": "85259",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Clinical Trials Referral Office",
                            "role": "CONTACT",
                            "phone": "855-776-0015",
                            "email": "mayocliniccancerstudies@mayo.edu"
                        },
                        {
                            "name": "Javier L. Munoz, M.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.50921,
                        "lon": -111.89903
                    }
                },
                {
                    "facility": "Mayo Clinic in Rochester",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55905",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Clinical Trials Referral Office",
                            "role": "CONTACT",
                            "phone": "855-776-0015",
                            "email": "mayocliniccancerstudies@mayo.edu"
                        },
                        {
                            "name": "Kah Whye Peng, Ph.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Nora Bennani, M.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "35175355",
                    "type": "RESULT",
                    "citation": "Cook J, Peng KW, Witzig TE, Broski SM, Villasboas JC, Paludo J, Patnaik M, Rajkumar V, Dispenzieri A, Leung N, Buadi F, Bennani N, Ansell SM, Zhang L, Packiriswamy N, Balakrishnan B, Brunton B, Giers M, Ginos B, Dueck AC, Geyer S, Gertz MA, Warsame R, Go RS, Hayman SR, Dingli D, Kumar S, Bergsagel L, Munoz JL, Gonsalves W, Kourelis T, Muchtar E, Kapoor P, Kyle RA, Lin Y, Siddiqui M, Fonder A, Hobbs M, Hwa L, Naik S, Russell SJ, Lacy MQ. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma. Blood Adv. 2022 Jun 14;6(11):3268-3279. doi: 10.1182/bloodadvances.2021006631."
                }
            ],
            "seeAlsoLinks": [
                {
                    "label": "Mayo Clinic Clinical Trials",
                    "url": "https://www.mayo.edu/research/clinical-trials"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009181",
                    "term": "Mycoses"
                },
                {
                    "id": "D000054243",
                    "term": "Vesicular Stomatitis"
                },
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                },
                {
                    "id": "D000008228",
                    "term": "Lymphoma, Non-Hodgkin"
                },
                {
                    "id": "D000016399",
                    "term": "Lymphoma, T-Cell"
                },
                {
                    "id": "D000016411",
                    "term": "Lymphoma, T-Cell, Peripheral"
                },
                {
                    "id": "D000009182",
                    "term": "Mycosis Fungoides"
                },
                {
                    "id": "D000017728",
                    "term": "Lymphoma, Large-Cell, Anaplastic"
                },
                {
                    "id": "D000013280",
                    "term": "Stomatitis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000001423",
                    "term": "Bacterial Infections and Mycoses"
                },
                {
                    "id": "D000007239",
                    "term": "Infections"
                },
                {
                    "id": "D000016410",
                    "term": "Lymphoma, T-Cell, Cutaneous"
                },
                {
                    "id": "D000009059",
                    "term": "Mouth Diseases"
                },
                {
                    "id": "D000009057",
                    "term": "Stomatognathic Diseases"
                },
                {
                    "id": "D000018353",
                    "term": "Rhabdoviridae Infections"
                },
                {
                    "id": "D000018701",
                    "term": "Mononegavirales Infections"
                },
                {
                    "id": "D000012327",
                    "term": "RNA Virus Infections"
                },
                {
                    "id": "D000014777",
                    "term": "Virus Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16070",
                    "name": "Stomatitis",
                    "asFound": "Stomatitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "relevance": "LOW"
                },
                {
                    "id": "M12058",
                    "name": "Multiple Myeloma",
                    "relevance": "LOW"
                },
                {
                    "id": "M27588",
                    "name": "Neoplasms, Plasma Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M18829",
                    "name": "Lymphoma, T-Cell",
                    "asFound": "T-cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18833",
                    "name": "Lymphoma, T-Cell, Peripheral",
                    "asFound": "Peripheral T-cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10955",
                    "name": "Leukemia, Myeloid",
                    "relevance": "LOW"
                },
                {
                    "id": "M18127",
                    "name": "Leukemia, Myeloid, Acute",
                    "relevance": "LOW"
                },
                {
                    "id": "M12136",
                    "name": "Mycoses",
                    "asFound": "Mycosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27596",
                    "name": "Vesicular Stomatitis",
                    "asFound": "Vesicular Stomatitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12137",
                    "name": "Mycosis Fungoides",
                    "asFound": "Mycosis Fungoides",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19941",
                    "name": "Lymphoma, Large-Cell, Anaplastic",
                    "asFound": "Anaplastic Large Cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11222",
                    "name": "Lymphoma, Non-Hodgkin",
                    "asFound": "Large cell lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10283",
                    "name": "Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4722",
                    "name": "Bacterial Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M4721",
                    "name": "Bacterial Infections and Mycoses",
                    "relevance": "LOW"
                },
                {
                    "id": "M18832",
                    "name": "Lymphoma, T-Cell, Cutaneous",
                    "relevance": "LOW"
                },
                {
                    "id": "M12019",
                    "name": "Mouth Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12017",
                    "name": "Stomatognathic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M20491",
                    "name": "Rhabdoviridae Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M20778",
                    "name": "Mononegavirales Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M15149",
                    "name": "RNA Virus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3947",
                    "name": "Multiple Myeloma",
                    "relevance": "LOW"
                },
                {
                    "id": "T4496",
                    "name": "Peripheral T-cell Lymphoma",
                    "asFound": "Peripheral T-cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3995",
                    "name": "Myeloid Leukemia",
                    "relevance": "LOW"
                },
                {
                    "id": "T182",
                    "name": "Acute Myeloid Leukemia",
                    "relevance": "LOW"
                },
                {
                    "id": "T188",
                    "name": "Acute Non Lymphoblastic Leukemia",
                    "relevance": "LOW"
                },
                {
                    "id": "T3986",
                    "name": "Mycosis Fungoides",
                    "asFound": "Mycosis Fungoides",
                    "relevance": "HIGH"
                },
                {
                    "id": "T367",
                    "name": "Anaplastic Large Cell Lymphoma",
                    "asFound": "Anaplastic Large Cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "T1792",
                    "name": "Dendritic Cell Tumor",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC07",
                    "name": "Mouth and Tooth Diseases"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007455",
                    "term": "Iodine"
                },
                {
                    "id": "D000007372",
                    "term": "Interferons"
                },
                {
                    "id": "D000016899",
                    "term": "Interferon-beta"
                },
                {
                    "id": "D000074324",
                    "term": "Ipilimumab"
                },
                {
                    "id": "C000627974",
                    "term": "Cemiplimab"
                },
                {
                    "id": "D000007136",
                    "term": "Immunoglobulins"
                },
                {
                    "id": "D000007074",
                    "term": "Immunoglobulin G"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000000998",
                    "term": "Antiviral Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000891",
                    "term": "Anti-Infective Agents, Local"
                },
                {
                    "id": "D000014131",
                    "term": "Trace Elements"
                },
                {
                    "id": "D000018977",
                    "term": "Micronutrients"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M302522",
                    "name": "Cemiplimab",
                    "asFound": "RAD",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M1348",
                    "name": "Ipilimumab",
                    "asFound": "Enrolled",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10488",
                    "name": "Iodine",
                    "asFound": "Patient Outcomes",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10407",
                    "name": "Interferons",
                    "asFound": "Food",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19244",
                    "name": "Interferon-beta",
                    "asFound": "Cervical Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "asFound": "Eligible",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10122",
                    "name": "Immunoglobulin G",
                    "asFound": "Kcal",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4230",
                    "name": "Antibodies, Monoclonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M19117",
                    "name": "Immunoglobulins, Intravenous",
                    "relevance": "LOW"
                },
                {
                    "id": "M229695",
                    "name": "Cadexomer iodine",
                    "relevance": "LOW"
                },
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4215",
                    "name": "Anti-Infective Agents, Local",
                    "relevance": "LOW"
                },
                {
                    "id": "M21009",
                    "name": "Micronutrients",
                    "relevance": "LOW"
                },
                {
                    "id": "M16885",
                    "name": "Trace Elements",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Micro",
                    "name": "Micronutrients"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}